Inhibítor plazminogénového aktivátora (PAI-1) a diabetes mellitus. II. PAI-1 pri inzulínrezistentných stavoch
[Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. II. PAI-1 in insulin resistant conditions]
Language Slovak Country Czech Republic Media print
Document type English Abstract, Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
9820087
- MeSH
- Diabetes Mellitus blood MeSH
- Plasminogen Activator Inhibitor 1 blood MeSH
- Insulin Resistance * MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Plasminogen Activator Inhibitor 1 MeSH
Insulin resistance (IR) is associated with an elevated PAI-1 level and by correlation with insulin and triacylglycerol (TG) levels. While in IR non-diabetics this relationship is close, in patients with NIDDM the mutual relationship is less marked and there are other factors which raise the PAI-1 levels such as proinsulin, oxidation stress or cytokines. Therefore achievement of satisfactory metabolic control, reduction of insulin and TG levels need not be associated with normalization of PAI-1. As it is an independent risk factor of atherosclerosis, further examinations are necessary in order to differentiate in more detail the possible causes of its rising level in order to obtain a rational basis for effective therapy.
